190 related articles for article (PubMed ID: 34452592)
21. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
24. Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong VW; Shipkova M; von Ahsen N; Oellerich M
Ther Drug Monit; 2004 Apr; 26(2):220-6. PubMed ID: 15228169
[TBL] [Abstract][Full Text] [Related]
25. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
26. TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Wray L; Vujkovic M; McWilliams T; Cannon S; Devidas M; Stork L; Aplenc R
Pediatr Blood Cancer; 2014 Nov; 61(11):2086-8. PubMed ID: 24737678
[TBL] [Abstract][Full Text] [Related]
27. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
[TBL] [Abstract][Full Text] [Related]
28. Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers.
Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Martínez-Ingelmo C; Ortega-Ruíz L; Sarmiento-Iglesias C; Herrador C; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):449-455. PubMed ID: 30346660
[TBL] [Abstract][Full Text] [Related]
29. [New techniques for optimization of thiopurine therapy in leukemia and transplantation].
Loennechen T; Lysaa RA; Giverhaug T; Sylte I; Mathiesen LE; Aarbakke J
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1107-10. PubMed ID: 12043054
[TBL] [Abstract][Full Text] [Related]
30. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells.
Karim H; Ghalali A; Lafolie P; Vitols S; Fotoohi AK
Biochem Biophys Res Commun; 2013 Jul; 437(2):280-6. PubMed ID: 23811272
[TBL] [Abstract][Full Text] [Related]
31. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L; Cartwright CS; Wade R; Vora A
Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
[TBL] [Abstract][Full Text] [Related]
32. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
[TBL] [Abstract][Full Text] [Related]
34. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
35. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia.
Kapoor G; Sinha R; Naithani R; Chandgothia M
Leuk Res; 2010 Aug; 34(8):1023-6. PubMed ID: 20153897
[TBL] [Abstract][Full Text] [Related]
36. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
Silva MR; de Oliveira BM; Viana MB; Murao M; Romanha AJ
Ther Drug Monit; 2008 Dec; 30(6):700-4. PubMed ID: 19057372
[TBL] [Abstract][Full Text] [Related]
37. Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.
Liu C; Yang W; Pei D; Cheng C; Smith C; Landier W; Hageman L; Chen Y; Yang JJ; Crews KR; Kornegay N; Karol SE; Wong FL; Jeha S; Sandlund JT; Ribeiro RC; Rubnitz JE; Metzger ML; Pui CH; Evans WE; Bhatia S; Relling MV
Clin Pharmacol Ther; 2017 Mar; 101(3):373-381. PubMed ID: 27564568
[TBL] [Abstract][Full Text] [Related]
38. The thiopurines: an update.
Coulthard S; Hogarth L
Invest New Drugs; 2005 Dec; 23(6):523-32. PubMed ID: 16267626
[TBL] [Abstract][Full Text] [Related]
39. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.
McLeod HL; Relling MV; Liu Q; Pui CH; Evans WE
Blood; 1995 Apr; 85(7):1897-902. PubMed ID: 7703493
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions.
Lennard L
Ther Drug Monit; 1998 Oct; 20(5):527-31. PubMed ID: 9780130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
